Avastin Has Similar Effect to Lucentis in Treating Most Common Cause of Blindness in the Developed W

The findings will also appear online shortly in the leading journal Ophthalmology
Wet AMD is a common cause of loss of vision in older people In the UK around 70 per cent of people will experience severe loss of sight within two years of being diagnosed
For four years a team of scientists and eye specialists from 23 hospitals and UK universities including Queens University Belfast University of Bristol University of Liverpool University of Southampton and University of Oxford have worked to investigate whether Lucentis and Avastin are equally effective
610 people with wet AMD entered a trial known as IVAN which is one of the largest ever carried out in the field of eye disease in the UK
The IVAN studys one year results show there was no functional difference in the effects of both drugs and that the effects of Lucentis and Avastin on preventing vision loss were similar
The study also indicates that in the UK the NHS could save 845 million annually based on injecting 17295 eyes each year by switching from Lucentis to Avastin and administering the treatment on an asneeded basis
Patients received injections of the drug into the affected eye every month for the first three Groups were then subdivided to receive either injections at every visit thereafter or only if the specialist decided there was persistent disease
The study also investigated whether treatment as needed is as effective as monthly treatment and revealed that giving the drugs as needed compared to regularly every month resulted in almost identical levels of vision The as needed group received on average seven injections over the first year compared to 12 for the monthly treatment group
Professor Usha Chakravarthy of Queens University Belfasts Centre for Vision and Vascular Science who led the research study team said The IVAN results at the end of the first year show that Lucentis and Avastin have similar effectiveness Regardless of the drug received or treating monthly or as needed sight in the affected eye improved by between one and two lines on a standard eye test
The one year results from the IVAN study complement the one year findings of a sister study CATT performed in the United States which reported last year In addition people in IVAN had their ability to read small print and their reading speed tested and these tests also showed no difference between drugs or methods of treatment
With respect to possible adverse effects of the drugs in IVAN a slightly higher rate of arteriothromboembolic events mainly heart attacks and strokes or heart failure was observed among people treated with Lucentis compared with Avastin which was not observed in CATT When the results of the two trials were combined no difference in heart attacks or strokes was observed between the two drugs
Both IVAN and CATT have consistently shown no difference in mortality between the groups receiving different drugs in the elderly study populations but both found a slightly higher rate of other serious adverse events in those who received Avastin This evidence became stronger when the results were combined
The researchers state that the findings in relation to adverse events may not be attributed to Avastin directly due to a number of reasons including that events were more common in patients treated less frequently and that they arose mainly from hospitalisations for a wide variety of causes not previously associated with either drug
The IVAN study was funded by the National Institute for Health Research Health Technology Assessment NIHR HTA programme
Belfast Health and Social Care Trust sponsored the study Professor Ian Young Director of Research and Development at the Trust said Clinical trials of this standard and breadth are of vital importance to the NHS and our clinicians in enabling us to provide optimal patient care I congratulate the research team in reaching this milestone in such a challenging study
The IVAN study is continuing to follow participants to two years A more detailed analysis will be presented when the two year time point is reached
The hospitals and universities involved in the trial include Addenbrookes Hospital Cambridge Aintree University Hospitals NHS Foundation Trust Aston University Day Hospital Birmingham Blackburn Royal Infirmary Blackpool Victoria Hospital Bradford Royal Infirmary Brighton and Sussex University Hospital Bristol Eye Hospital Frimley Park Hospital Surrey Maidstone Hospital Manchester Royal Eye Hospital New Cross Hospital Wolverhampton Oxford Eye Hospital at the Oxford University Hospitals NHS Trust Queen Elisabeth Hospital Kings Lynn Queens Medical Centre Nottingham Royal Victoria Hospital Belfast Royal Victoria Infirmary Newcastle Southampton General Hospital Southend Hospital St Pauls Eye Unit Royal Liverpool University Hospital Sunderland Eye Hospital The Birmingham and Midland Eye Centre The Royal Hallamshire Hospital Sheffield and Torbay Hospital

Date : 07 May, 2012
Reference : http://www.sciencedaily.com/releases/2012/05/120506160147.htm

Back to News
Featured Hospitals Listing
MIOT Hospitals
4/112, Mount Poonamalle Road Manapakkam Chennai Tamil Nadu (India)
Phone : 044 2249 2288
Email : hip@miothospitals.com
Website URL : Available